Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846463 · ClinicalTrials.gov registry record · Phase 2
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
A Phase 2 study of Diffuse Large B Cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06846463 is a Phase 2 study of Diffuse Large B Cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 21 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06846463, a Phase 2 study of Diffuse Large B Cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
Conditions Studied
Interventions
- DRUG Zanubrutinib
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2032-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846463
The ClinicalTrials.gov registry entry for NCT06846463 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT06846463 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06846463 about?
NCT06846463 is a clinical study titled "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+". This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
What is the current status of trial NCT06846463?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2025-05-27. Estimated completion is 2032-07-31.
What conditions does trial NCT06846463 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT06846463?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT06846463?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846463 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Explore more on PlainTrial
Diffuse Large B Cell Lymphoma
All registered trials for this condition
DLBCL - Diffuse Large B Cell Lymphoma
All registered trials for this condition
Virginia
All trials with a study site in Virginia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.